NASDAQ:NUVA NuVasive (NUVA) Stock Forecast, Price & News $39.42 +0.87 (+2.26%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$38.64▼$39.5250-Day Range$36.71▼$44.1552-Week Range$35.17▼$56.79Volume544,789 shsAverage Volume999,279 shsMarket Capitalization$2.07 billionP/E Ratio115.94Dividend YieldN/APrice Target$50.98 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media NuVasive MarketRank™ ForecastAnalyst RatingHold2.18 Rating ScoreUpside/Downside29.3% Upside$50.98 Price TargetShort InterestBearish17.71% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.36Based on 5 Articles This WeekInsider TradingN/AProj. Earnings Growth17.35%From $2.19 to $2.57 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.32 out of 5 starsMedical Sector374th out of 983 stocksSurgical & Medical Instruments Industry38th out of 98 stocks 3.1 Analyst's Opinion Consensus RatingNuVasive has received a consensus rating of Hold. The company's average rating score is 2.18, and is based on 2 buy ratings, 9 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $50.98, NuVasive has a forecasted upside of 29.3% from its current price of $39.42.Amount of Analyst CoverageNuVasive has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted17.71% of the outstanding shares of NuVasive have been sold short.Short Interest Ratio / Days to CoverNuVasive has a short interest ratio ("days to cover") of 9.6.Change versus previous monthShort interest in NuVasive has recently increased by 88.44%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNuVasive does not currently pay a dividend.Dividend GrowthNuVasive does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NUVA. Previous Next 1.9 News and Social Media Coverage News SentimentNuVasive has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for NuVasive this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for NUVA on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NuVasive insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.53% of the stock of NuVasive is held by insiders. Previous Next 4.4 Earnings and Valuation Earnings GrowthEarnings for NuVasive are expected to grow by 17.35% in the coming year, from $2.19 to $2.57 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NuVasive is 115.94, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 136.32.Price to Earnings Ratio vs. SectorThe P/E ratio of NuVasive is 115.94, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 138.54.Price to Earnings Growth RatioNuVasive has a PEG Ratio of 0.87. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioNuVasive has a P/B Ratio of 2.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About NuVasive (NASDAQ:NUVA) StockNuVasive, Inc. engages in the development, manufacture, sale, and provision of procedural solutions for spine surgery. It offers a comprehensive portfolio of procedurally integrated spine surgery solutions, including surgical access instruments, spinal implants, fixation systems, biologics, and enabling technologies, as well as systems and services for intraoperative neuromonitoring. The company was founded by Alexis V. Lukianov on July 21, 1997 and is headquartered in San Diego, CA.Read More Receive NUVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NuVasive and its competitors with MarketBeat's FREE daily newsletter. Email Address NUVA Stock News HeadlinesMay 31, 2023 | markets.businessinsider.comWhat 5 Analyst Ratings Have To Say About NuVasiveMay 31, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for NuVasiveJune 3, 2023 | Legacy Research (Affiliate) (Ad)“One-Stock Millionaire” IGNORES 99.9% of the MarketDuring the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.May 31, 2023 | americanbankingnews.comNuVasive (NASDAQ:NUVA) Now Covered by StockNews.comMay 26, 2023 | yahoo.comLocal medical tech company part of $3.1B merger dealMay 24, 2023 | finance.yahoo.comGlobal Spinal Fusion Market Report to 2033: Players Include Medtronic, NuVasive, DePuy Synthes and Globus MedicalMay 24, 2023 | americanbankingnews.comNuVasive (NASDAQ:NUVA) Coverage Initiated at StockNews.comMay 17, 2023 | marketwatch.comOrthobiologics Market Set to Witness Huge Growth by 2029 | Medtronic, NuVasive, Inc.June 3, 2023 | Legacy Research (Affiliate) (Ad)“One-Stock Millionaire” IGNORES 99.9% of the MarketDuring the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.May 17, 2023 | americanbankingnews.comNuVasive, Inc. (NASDAQ:NUVA) Receives Average Rating of "Hold" from AnalystsMay 15, 2023 | markets.businessinsider.comRBC Capital Reaffirms Their Buy Rating on NuVasive (NUVA)May 15, 2023 | americanbankingnews.comNuVasive (NASDAQ:NUVA) Price Target Raised to $56.00May 14, 2023 | americanbankingnews.comNuVasive (NASDAQ:NUVA) Receives New Coverage from Analysts at StockNews.comMay 12, 2023 | marketwatch.com2023 Spine Surgery Medical Equipment Market: Latest Innovative Growth Strategies Forecast till 2031May 12, 2023 | markets.businessinsider.comExpert Ratings for NuVasiveMay 12, 2023 | msn.comNuVasive Non-GAAP EPS of $0.47 beats by $0.05, revenue of $307.7M beats by $9.26MMay 12, 2023 | markets.businessinsider.comNuVasive Announces First Quarter 2023 Financial ResultsMay 12, 2023 | msn.comBarclays Maintains Nuvasive (NUVA) Overweight RecommendationMay 11, 2023 | msn.comRBC Capital Reiterates Nuvasive (NUVA) Outperform RecommendationMay 11, 2023 | msn.comMorgan Stanley Maintains Nuvasive (NUVA) Equal-Weight RecommendationMay 10, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ) and NuVasive (NUVA)May 10, 2023 | chron.comNuVasive: Q1 Earnings SnapshotMay 10, 2023 | msn.comNuVasive's Earnings: A PreviewMay 10, 2023 | markets.businessinsider.comNuVasive is about to announce its earnings — here's what to expectMay 9, 2023 | americanbankingnews.comNuVasive (NUVA) Set to Announce Earnings on WednesdayMay 5, 2023 | finance.yahoo.comQ1 2023 Globus Medical Inc Earnings CallMay 4, 2023 | finance.yahoo.comNuVasive Announces Conference Call and Webcast of First Quarter 2023 ResultsSee More Headlines NUVA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NUVA Company Calendar Last Earnings5/10/2023Today6/03/2023Next Earnings (Estimated)8/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:NUVA CUSIP67070410 CIK1142596 Webwww.nuvasive.com Phone(858) 909-1800Fax800-475-9134Employees3,000Year Founded1997Price Target and Rating Average Stock Price Forecast$50.98 High Stock Price Forecast$58.00 Low Stock Price Forecast$44.50 Forecasted Upside/Downside+29.3%Consensus RatingHold Rating Score (0-4)2.18 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)$0.34 Trailing P/E Ratio115.94 Forward P/E Ratio18.00 P/E Growth0.87Net Income$40.41 million Net Margins1.66% Pretax Margin2.35% Return on Equity11.82% Return on Assets4.60% Debt Debt-to-Equity Ratio0.51 Current Ratio1.20 Quick Ratio0.68 Sales & Book Value Annual Sales$1.20 billion Price / Sales1.72 Cash Flow$5.13 per share Price / Cash Flow7.69 Book Value$16.66 per share Price / Book2.37Miscellaneous Outstanding Shares52,450,000Free Float52,171,000Market Cap$2.07 billion OptionableOptionable Beta1.08 Social Links Key ExecutivesJ. Christopher BarryChief Executive Officer & DirectorDale WolfSenior Vice President-Global OperationsMatthew K. HarbaughChief Financial Officer & Executive Vice PresidentKyle MaloneVice President-Scientific AffairsRyan DonahoeChief Technology Officer & Senior Vice PresidentKey CompetitorsAlphatecNASDAQ:ATECAtriCureNASDAQ:ATRCCardiovascular SystemsNASDAQ:CSIIIntegra LifeSciencesNASDAQ:IARTOrthofix MedicalNASDAQ:OFIXView All CompetitorsInstitutional OwnershipPrelude Capital Management LLCBought 55,716 shares on 6/1/2023Ownership: 0.106%ProShare Advisors LLCBought 6,804 shares on 5/26/2023Ownership: 0.030%Ameriprise Financial Inc.Sold 67,746 shares on 5/22/2023Ownership: 0.486%Thrivent Financial for LutheransSold 2,966,154 shares on 5/17/2023Ownership: 0.483%Azimuth Capital Investment Management LLCSold 2,575 shares on 5/16/2023Ownership: 0.027%View All Institutional Transactions NUVA Stock - Frequently Asked Questions Should I buy or sell NuVasive stock right now? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NuVasive in the last twelve months. There are currently 9 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NUVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NUVA, but not buy additional shares or sell existing shares. View NUVA analyst ratings or view top-rated stocks. What is NuVasive's stock price forecast for 2023? 11 analysts have issued 1 year price targets for NuVasive's stock. Their NUVA share price forecasts range from $44.50 to $58.00. On average, they anticipate the company's share price to reach $50.98 in the next year. This suggests a possible upside of 29.3% from the stock's current price. View analysts price targets for NUVA or view top-rated stocks among Wall Street analysts. How have NUVA shares performed in 2023? NuVasive's stock was trading at $41.24 at the start of the year. Since then, NUVA stock has decreased by 4.4% and is now trading at $39.42. View the best growth stocks for 2023 here. Are investors shorting NuVasive? NuVasive saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 9,290,000 shares, an increase of 88.4% from the April 30th total of 4,930,000 shares. Based on an average daily volume of 966,900 shares, the short-interest ratio is currently 9.6 days. View NuVasive's Short Interest. When is NuVasive's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023. View our NUVA earnings forecast. How were NuVasive's earnings last quarter? NuVasive, Inc. (NASDAQ:NUVA) issued its quarterly earnings results on Wednesday, May, 10th. The medical device company reported $0.47 earnings per share for the quarter, beating analysts' consensus estimates of $0.41 by $0.06. The medical device company had revenue of $307.71 million for the quarter, compared to the consensus estimate of $298.43 million. NuVasive had a net margin of 1.66% and a trailing twelve-month return on equity of 11.82%. During the same quarter in the prior year, the company posted $0.54 EPS. What ETFs hold NuVasive's stock? ETFs with the largest weight of NuVasive (NASDAQ:NUVA) stock in their portfolio include IQ Merger Arbitrage ETF (MNA), ProShares Merger ETF (MRGR), Invesco S&P SmallCap Health Care ETF (PSCH), SPDR S&P Health Care Equipment ETF (XHE), Principal Healthcare Innovators ETF (BTEC), Invesco Nasdaq Future Gen 200 ETF (QQQS), iShares S&P Small-Cap 600 Value ETF (IJS) and SPDR S&P 600 Small CapValue ETF (SLYV). How will NuVasive's stock buyback program work? NuVasive announced that its Board of Directors has authorized a stock repurchase plan on Tuesday, November 9th 2021, which permits the company to buyback $100,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to buy up to 3.5% of its shares through open market purchases. Shares buyback plans are often a sign that the company's board believes its shares are undervalued. What guidance has NuVasive issued on next quarter's earnings? NuVasive issued an update on its FY 2023 earnings guidance on Friday, May, 12th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.27 billion-$1.30 billion, compared to the consensus revenue estimate of $1.28 billion. What is Chris Barry's approval rating as NuVasive's CEO? 59 employees have rated NuVasive Chief Executive Officer Chris Barry on Glassdoor.com. Chris Barry has an approval rating of 88% among the company's employees. What other stocks do shareholders of NuVasive own? Based on aggregate information from My MarketBeat watchlists, some companies that other NuVasive investors own include BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), Intel (INTC), Alibaba Group (BABA), (MDVN) (MDVN), Micron Technology (MU), Bank of America (BAC), Gilead Sciences (GILD) and Applied Materials (AMAT). What is NuVasive's stock symbol? NuVasive trades on the NASDAQ under the ticker symbol "NUVA." Who are NuVasive's major shareholders? NuVasive's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Dimensional Fund Advisors LP (2.98%), Arrowstreet Capital Limited Partnership (2.12%), Geode Capital Management LLC (1.93%), Two Sigma Advisers LP (1.90%), Stephens Investment Management Group LLC (1.53%) and Burgundy Asset Management Ltd. (1.49%). Insiders that own company stock include James Christopher Barry, Lucas Vitale, Massimo Calafiore and Matthew Link. View institutional ownership trends. How do I buy shares of NuVasive? Shares of NUVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is NuVasive's stock price today? One share of NUVA stock can currently be purchased for approximately $39.42. How much money does NuVasive make? NuVasive (NASDAQ:NUVA) has a market capitalization of $2.07 billion and generates $1.20 billion in revenue each year. The medical device company earns $40.41 million in net income (profit) each year or $0.34 on an earnings per share basis. How many employees does NuVasive have? The company employs 3,000 workers across the globe. Does NuVasive have any subsidiaries? The following companies are subsidiares of NuVasive: Biotronic NeuroNetwork, Ellipse Technologies, NuVasive Clinical Services Monitoring Inc., NuVasive Japan KK, NuVasive Specialized Orthopedics Inc., NuVasive Technology International Limited, SafePassage, Simplify Medical, and Vertera Spine.Read More How can I contact NuVasive? NuVasive's mailing address is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. The official website for the company is www.nuvasive.com. The medical device company can be reached via phone at (858) 909-1800, via email at investorrelations@nuvasive.com, or via fax at 800-475-9134. This page (NASDAQ:NUVA) was last updated on 6/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NuVasive, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.